miscsubjectsAI governance
Evidence review

TB-500 and GLP-1 Agonists: Evidence-Graded Look at Repair Pathways During Weight Management

bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `tb-500-glp-1`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/tb-500-glp-1

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-glp-1/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tb-500-glp-1/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tb-500-glp-1/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tb-500-glp-1/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

This topic: TB-500 (thymosin beta-4) is studied for repair-cell migration and actin regulation — cells that need to reach an injury and rebuild structure. That is regeneration: move repair machinery to the damage.

Why TB-500 might help you

  1. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
  2. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
  3. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

Why GLP-1 agonists (class) matters for you

  1. Drug: GLP-1 agonists (class)
  2. What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.
  3. Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • TB-500 → inflammation clearance / repair-cell migration

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 2
  • Claims tagged human evidence: 2
  • Claims tagged preclinical (animal/lab): 1
  • Claims tagged anecdotal: 1
  • Reddit posts catalogued: 1
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 4

Quantified confidence (this ledger): 0.35 / 1.00 — low–moderate — mostly preclinical

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

TB-500 for Injury Recovery | What the Research Actually Shows (source s1)

Summarizes phase 1 safety and phase 2 eye data for thymosin beta-4.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review (source s2)

Comprehensive 2026 scoping review mapping evidence levels and gaps.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

What people say on Reddit

Trying the “Wolverine Stack” (BPC-157 + TB-500) — Reddit, r/ACL (source s35)

Example user report of perceived healing improvement with TB-500 stack post-ACL surgery.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Explore this article's relationships

GLP-1 agonists · drug map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
Evidence · 4 sources · swipe →chain 803c801d66dc · verify chain · provenance
Evidence ledger 4 · tier-ranked · API
human
Phase 1 data on recombinant thymosin beta-4 showed good tolerability in 84 healthy volunteers with no serious adverse events.
sources: s1
humanlow confidence
GLP-1 agonists produce weight loss that lowers mechanical load on joints and spine while carrying potential lean-mass tradeoffs.
sources: s15
preclinicallow confidence
A 2026 scoping review of 80 studies found human evidence for thymosin beta-4 concentrated in ocular and wound settings with no direct musculoskeletal interventional trials and minimal TB-500-specific data.
sources: s2
anecdotallow confidence
Anecdotal reports on Reddit describe subjective faster tendon healing with TB-500 containing stacks, but lack controls or verification.
sources: s35
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-29 23:38
TB-500 and GLP-1 Agonists: Evidence-Graded Look at Repair Pathways During Weight Management · 4 claims · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: TB 500 for Glp 1
Slug: tb-500-glp-1
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_focus","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"tb-500","name":"TB-500"}],"drugs_in_scope":["glp1-agonists"],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down","degenerative_why":[],"degener
it output
{
  "slug": "tb-500-glp-1",
  "title": "TB-500 and GLP-1 Agonists: Evidence-Graded Look at Repair Pathways During Weight Management",
  "body": "## What's breaking down\n\nNo single condition profile matches the slug, but the cross points to repair needs that arise when using GLP-1 agonists for weight loss. GLP-1 drugs drive substantial fat loss. That loss lowers body mass and can ease compressive forces on joints and the spine. At the same time, rapid change can involve inflammation that lingers, slower cell migration to stressed tissues, and shifts in muscle and connective tissue that affect long-term structure. The core issue is whether breakdown outruns repair. Inflammation clearance and directed cell movement to damage sites are layers that often stall first. Actin organization inside cells also matters because it governs how repair cells crawl and rebuild. When these layers lag, recovery from everyday wear or from the metabolic shifts of weight loss can slow.\n\n## Why TB-500 might help you\n\n1. What keeps failing: Repair cells not reaching injury sites quickly enough, inflammation that stays active instead of clearing, and disorganized actin inside cells that limits movement and structure rebuilding.\n2. What TB-500 is studied to do: It mimics a key segment of thymosin beta-4, which is examined for promoting cell migration along actin filaments, supporting angiogenesis,
e8052e8c2060a8cc
Machine verification: /api/articles/tb-500-glp-1/contributions
Ask this article · 7 suggested prompts

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "Phase 1 data on recombinant thymosin beta-4 showed good tolerability in 84 healthy volunteers with no serious adverse events."?
ask tb-500-glp-1 claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "GLP-1 agonists produce weight loss that lowers mechanical load on joints and spine while carrying potential lean-mass tradeoffs."?
ask tb-500-glp-1 claim c3 · paste includes §SELF
What does the ledger say about this (preclinical tier): "A 2026 scoping review of 80 studies found human evidence for thymosin beta-4 concentrated in ocular and wound settings with no direct muscul…"?
ask tb-500-glp-1 claim c1 · paste includes §SELF
What does the ledger say about this (anecdotal tier): "Anecdotal reports on Reddit describe subjective faster tendon healing with TB-500 containing stacks, but lack controls or verification."?
ask tb-500-glp-1 claim c4 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Example user report of perceived healing improvement with TB-500 stack post-ACL surgery."
ask tb-500-glp-1 source s35 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about TB-500 and GLP-1 Agonists: Evidence-Graded Look at Repair Pathways During Weight Management — and what would you need me to tell you first?
ask tb-500-glp-1 condition gaps · paste includes §SELF
What good and bad outcomes are documented for TB-500 and GLP-1 Agonists: Evidence-Graded Look at Repair Pathways During Weight Management (studies vs anecdotes)?
ask tb-500-glp-1 good bad experiences · paste includes §SELF
tb-500-glp-1 · posted 2026-06-29 · updated 2026-07-17 · 1 prior revision · grok/grok-4.3
Ledger API & provenance
Provenance · 2 model passes · 44980 tokens · $0 · 2 models
chain head ad87a224bad5029c
write grok/grok-4.3 · 2026-06-29 23:38 · 44980 tok · 83ecca31fe22
voxel_divide owner · 2026-07-17 02:42 · tokens unrecorded · ad87a224bad5
verify chain →
Live ledger · 17 payloads · 2 turns
recent activity · inspect
JCI_TRAFFIC jci · HTTP 200 · 2026-07-27 19:43
JCI_TRAFFIC jci · HTTP 200 · 2026-07-27 16:54
JCI_CLASSIFY jci · HTTP 200 · 2026-07-27 16:54
JCI_TRAFFIC jci · HTTP 200 · 2026-07-27 16:30
JCI_TRAFFIC jci · HTTP 200 · 2026-07-27 11:27
JCI_TRAFFIC jci · HTTP 200 · 2026-07-27 10:02
view full ledger & cards →
REST + ledger
read GET /api/articles/tb-500-glp-1 · GET /api/articles/tb-500-glp-1?format=post (the editable body)
create/replace POST /api/articles/tb-500-glp-1 · PUT /api/articles/tb-500-glp-1 (replace, keeps revision) · PATCH /api/articles/tb-500-glp-1 (merge)
delete DELETE /api/articles/tb-500-glp-1
writes need header x-terminal-key
LLM bundle GET /api/articles/tb-500-glp-1/bundle?format=markdown — body + claims + sources + provenance + manifest
post claim POST /api/protocol/claim · iMessage claim tb-500-glp-1|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →